FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Medical Devices

SeaStar Breakthrough Status for Cytopheretic Device

FDA grants SeaStar Medical Holding a breakthrough device designation for its cell-directed Selective Cytopheretic Device for use in intensive care uni...

Medical Devices

Hamilton Medical Ventilators Recalled

Hamilton Medical recalls its Hamilton-C1, T1, MR-1 ventilators because the capacitators may leak electrolyte fluid onto the ventilators control board....

latest-news-card-1
Human Drugs

Courts Could Cut FDA Labeling Enforcement: Avorn

Harvard Medical School professor Jerry Avorn says recent court decisions banning compelled speech could be interpreted to stop FDA from requiring full...

latest-news-card-1
Medical Devices

FCA Cases Look at Cybersecurity: Attorneys

Seven Gibson Dunn attorneys say the government is pursuing False Claims Act cases involving cybersecurity claims by device manufacturers.

latest-news-card-1
Biologics

BrainStorm Pulls NurOwn BLA

BrainStorm Cell Therapeutics says it is withdrawing a BLA for its NurOwn ALS treatment technology and will work with FDA on a path forward for the tre...

latest-news-card-1
Federal Register

FDA Posts 6 Approved Info Collections

Federal Register notice: FDA posts a list of six information collections that have been approved by OMB.

latest-news-card-1
Federal Register

Naropin Not Withdrawn Due to Safety/Efficacy

Federal Register notice: FDA determines that Fresenius Kabi USAs Naropin (ropivacaine HCl) solution was not withdrawn due to safety or effectiveness r...

latest-news-card-1
Medical Devices

Non-Invasive Monitoring Enforcement Guide

FDA publishes an immediately effective guidance removing an expiration for some enforcement policies for certain non-invasive remote monitoring device...

latest-news-card-1
Biologics

FDA Approves UCBs Psoriasis Therapy

FDA approves a UCB BLA for Bimzelx (bimekizumab-bkzx) for treating moderate-to-severe plaque psoriasis in adults who are candidates for systemic thera...

latest-news-card-1
Human Drugs

FDA Clears Intellia IND for Phase 3 Trial

FDA clears an Intellia Therapeutics IND to permit a Phase 3 trial of its NTLA-2001 to treat transthyretin amyloidosis with cardiomyopathy.